<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322735</url>
  </required_header>
  <id_info>
    <org_study_id>HenanCH284</org_study_id>
    <nct_id>NCT03322735</nct_id>
  </id_info>
  <brief_title>Study of BCMA CAR-T in Multiple Myeloma</brief_title>
  <official_title>A Study of BCMA CAR-T Cells for Patients With Relapse and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Pregene (ShenZhen) Biotechnology Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and
      refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy. The
      CAR enables the T cell to recognize and kill the MM cells through the recognition of BCMA, a
      protein expressed of the surface of the malignant plasma cells in MM patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>number of participants with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence of the BCMA CAR+ T cells</measure>
    <time_frame>1 year</time_frame>
    <description>determine duration of in vivo survival of BCMA CAR-T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-tumor responses of BCMA CAR-T cells</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>anti-tumor response of BCMA CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Cyclophosphamide patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days.
Drug: Fludarabine Fludarabine 25-30mg/m2/day IV for 3 days. Biological: BCMA CAR-T BCMA CAR-T cells will be administered after completion of the chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25-30mg/m2/day IV for 3 days</description>
    <arm_group_label>anti-tumor response of BCMA CAR-T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>cyclophosphamide 0.6-0.8g/m2/day IV for 2 days</description>
    <arm_group_label>anti-tumor response of BCMA CAR-T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCMA CAR-T</intervention_name>
    <description>BCMA CAR-T cells will be administered after completion of the chemotherapy.</description>
    <arm_group_label>anti-tumor response of BCMA CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. 18 years to 70 years, expected survival &gt; 3 months;

          -  2. Confirmed diagnosis of active MM as defined by IMWG. BCMA expression of the
             malignant cells must be detected by immunohistochemistry or by flow cytometry.

          -  3. BCMA-expressing B cell malignancy must be assured and must be relapsed or
             refractory disease.；

          -  4. ECOG performance status of 0-2;

          -  5. Cardiac function: 1-2 levels; Liver: TBIL≤3ULN，AST ≤2.5ULN，ALT ≤2.5ULN; kidney:
             Cr≤1.25ULN;

          -  6. No serious allergic constitution;

          -  7. No other serous diseases that conflicts with the clinical program;

          -  8. No other cancer history;

          -  9. female participants of reproductive potential must have a negative serum pregnancy
             test;

          -  10. Subjects must have signed written, informed consent.

        Exclusion Criteria:

          -  1. Pregnant or lactating women;

          -  2. Uncontrolled active infection, HIV infection, syphilis serology reaction positive;

          -  3. Active hepatitis B or hepatitis C infection;

          -  4. Recent or current use of glucocorticoid or other immunosuppressor;

          -  5. serious mental disorder;

          -  6. With severe cardiac, liver, renal insufficiency, diabetes and other diseases;

          -  7. Participate in other clinical research in the past three months; previously
             treatment with any gene therapy products;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongping Song</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongping Song</last_name>
    <phone>+86-13521186987</phone>
    <email>ph200811@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Affiliate to Zhengzhou University &amp; Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongping Song</last_name>
      <phone>+86-13521186987</phone>
      <email>ph200811@163.com</email>
    </contact>
    <investigator>
      <last_name>Yongping Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

